HEAD AND NECK SQUAMOUS CELL CARCINOMA

This study is testing a new immune therapy called CUE-101, both alone and combined with an existing drug (pembrolizumab), as a treatment given before surgery for advanced head and neck cancer caused by HPV-16. It will involve about 30 people with newly diagnosed cancer that canno…

This study is testing whether giving new drug combinations before surgery can help shrink tumors in people with advanced head and neck cancer. The goal is to see if these pre-surgery treatments can kill more cancer cells, potentially leading to better long-term results. About 120…

This early-stage study is testing a new radioactive antibody called LNTH-2403 in people with advanced colorectal, head and neck, lung, or breast cancer. The main goals are to see if a single dose is safe and to use special scans to see where the antibody goes in the body and if i…

This is the first study in humans testing a new cancer drug called QLS5316. Researchers want to find the safest dose and see if it helps control advanced solid tumors in patients who have run out of standard treatment options. The study will enroll 300 adults with various advance…

This study is testing whether doctors can safely lower radiation doses for people with HPV-positive throat cancer to reduce side effects while still keeping the cancer under control. It will enroll 132 adults who are having either surgery followed by radiation or radiation as the…

This study is testing a more personalized approach to radiation therapy given after surgery for head and neck cancer. The goal is to see if doctors can safely target radiation to smaller, specific areas to reduce common and severe side effects, without increasing the risk of the …

This study is testing a new three-drug combination as a first step before surgery for people with locally advanced head and neck cancer. The goal is to see if this approach can shrink or even eliminate the cancer in the tumor before it is removed, which may help prevent the cance…

This study is testing a two-part treatment for head and neck cancer that has returned or spread after standard treatments. Doctors will inject a modified virus (H101) designed to attack cancer cells directly into the tumor, combined with a targeted chemotherapy procedure (TACE) t…

This early-stage study is testing whether adding an experimental drug called decitabine can make an approved immunotherapy (nivolumab) work better against recurrent or spreading head and neck cancer. The main goals are to find the safest dose of the combination and see how it aff…

This study is testing whether a new combination of drugs given before and after surgery works as well as standard chemotherapy for people with advanced head and neck cancer. The goal is to see if this approach helps patients live longer and keeps the cancer from coming back. Rese…

This study aims to find the best treatment for people with advanced head and neck cancer who cannot safely take the standard chemotherapy drug, cisplatin. It will compare two different drug combinations, each given alongside targeted radiation therapy, in about 454 patients. The …

This early-stage trial is testing a new fluorescent drug called ABY-029. The goal is to see if it safely makes head and neck cancer tumors glow under special imaging during surgery, helping surgeons better see the cancer's edges. Researchers will compare two very small doses in 2…

This study aims to see if two simple blood tests can find HPV-related throat cancers early, before symptoms appear. It will enroll 10,000 men aged 50 and older with no symptoms. If successful, this could lead to a national screening program to catch these cancers sooner and impro…

This early-stage study is testing a new radioactive imaging agent called [18F]NOTA-ABY030. The goal is to see if it is safe and if it can help doctors more clearly see head and neck cancer on a PET/CT scan, especially when standard scans show unclear spots. Researchers hope this …